Related Experiment Video

Updated: Jun 21, 2026

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance
09:48

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance

Published on: February 17, 2023

Molecular mechanisms involved in obesity-associated insulin resistance: therapeutical approach

Sonia Fernández-Veledo1, Iria Nieto-Vazquez, Rocio Vila-Bedmar

  • 1Departamento de Bioquimica y Biologia Molecular II, Facultad de Farmacia, Universidad Complutense, 28040-Madrid, Spain. soferve@farm.ucm.es

Archives of Physiology and Biochemistry
|August 14, 2009
PubMed

Insights

Obesity-related inflammation contributes to insulin resistance, a key factor in type 2 diabetes (T2D). Treatments targeting inflammation and insulin signaling pathways can improve metabolic health.

Area of Science:

  • Metabolic disorders
  • Inflammation
  • Insulin resistance

Background:

  • Obesity-associated metabolic dysfunction involves chronic low-grade inflammation.
  • Pro-inflammatory mediators (TNF-alpha, IL-6) from adipocytes and macrophages impair insulin action.
  • Chronic hyperinsulinemia exacerbates insulin resistance.

Purpose of the Study:

  • To explore the molecular mechanisms underlying insulin resistance in obesity.
  • To investigate the role of inflammatory mediators and hyperinsulinemia in disrupting insulin signaling.
  • To evaluate the efficacy of pharmacological interventions in overcoming insulin resistance.

Main Methods:

  • Investigated the involvement of pro-inflammatory kinases and phosphatases in insulin signaling disruption.
  • Examined the effects of pro-inflammatory cytokines and hyperinsulinemia on Insulin Receptor Substrates (IRSs).

Main Results:

  • Pro-inflammatory cytokines and hyperinsulinemia disrupt insulin signaling pathways.
  • Specific pharmacological agents, PPAR and LXR agonists, demonstrate potential in reversing insulin resistance.
  • These agonists possess anti-inflammatory properties and modulate cytokine expression.

Conclusions:

  • Inflammation and hyperinsulinemia are critical in developing insulin resistance.
  • PPAR and LXR agonists offer a promising therapeutic strategy for managing obesity-related insulin resistance and T2D.
  • Targeting inflammatory pathways and insulin signaling is crucial for metabolic health.

More Related Videos

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)

Published on: January 7, 2018

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...